- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03762070
Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Observational study of a FDA cleared device, the CL Detect™ Rapid Test. Data for the 510(K) was supported by a sensitivity study conducted in Tunisia, Old world Leishamania major and a specificity study conducted in the United Sates. Sensitivity and specificity data collected recently in Peru (2014-2015), by the Instituto de Medicina Tropical Alexander von Humbolt, supports the idea that the sensitivity of the CL Detect™ Rapid Test can be drastically increased for New World Leishmania species. The study is a single trial, with two clinical sites, NAMRU-6, Puerto Maldonado and the Alexander von Humboldt Tropical Medicine Institute in Lima. The objective of the study is to determine the sensitivity and specificity of the FDA-cleared CL Detect™ Rapid Test, using an optimized test procedure determined from a pilot study conducted in Peru. Two modifications to the test procedure (marketed device instructions) are included in this study: 1) increase in extraction time in lysis buffer from 5 to 10 minutes to 20 to 30 minutes and 2) a 20 μl increase in the volume of the sample to add to the test strip, from 20 μl to 40 μl. The gold standard for Leishmania diagnosis, which is microscopic identification of amastigotes in stained lesion sample, will be used as a control.
Participants will be patients who present for medical consultation due to a suspected CL lesion. After obtaining informed consent and screening the participant for eligibility, we will collect and test at most 4 samples from the index lesion in the following order:
- one sample obtained with a dental broach for use with the CL Detect™ Rapid Test;
- one sample obtained by scraping for microscopic identification of amastigotes; and
- one sample obtained by scraping for Leishmania speciation by PCR; and
- when possible, (depending on the size of the lesion), one sample from a different site of the same lesion, obtained by scraping for use with the CL Detect™ Rapid Test. PCR analysis will be performed by NAMRU-6 for possible exploratory analyses including species identification. If the etiologies of the lesions that are negative for Leishmania are known, they will be reported. Participants with a positive diagnosis of leishmaniasis by microscopy or other methods will be referred for standard of care treatment in Peru by the attending physician of the Peruvian Ministry of Health. Treatment is not part of this study. If a participant's lesions are negative for Leishmania, standard of care follow-up testing will be performed, either at the study site, or (when indicated) in another hospital.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Max Grogl, Ph.D.
- Phone Number: 51-1-614-4159
- Email: max.grogl1.civ@mail.mil
Study Locations
-
-
-
Lima, Peru
- Recruiting
- Universidad Peruana Cayetano Heredia (UPCH)
-
Contact:
- Ana Ramos, M.D.
- Email: ana.ramos.t@upch.pe
-
Sub-Investigator:
- Alejandro Llanos-Cuentas, M.D., Ph.D
-
Puerto Maldonado, Peru
- Recruiting
- U.S. Naval Medical Research Center Unit No. 6 (NAMRU-6)
-
Contact:
- Luis Angel Rosales
- Phone Number: 51-982-328-888
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- At least 18 years of age and generally healthy.
- Able to provide written informed consent.
Index lesion present that is suspicious for CL, as defined by the following criteria for an index lesion:
- less than 2 months in age
- primarily ulcerative, i.e. not purely verrucous or nodular
- no clear clinical evidence of cellulitis
- location suitable for collecting samples by dental broach and scraping.
- Capable of understanding and complying with the protocol, in the opinion of the evaluator
Exclusion Criteria:
- Received treatment for leishmaniasis within the last 2 months prior to evaluation.
- In the opinion of the investigator, evidence of manipulation of the lesion.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The performance (sensitivity and specificity) of the CL Detect™ Rapid Test
Time Frame: 1 day
|
Sensitivity and specificity of CL Detect™ Rapid Test will be determined by comparing with the gold standard, microscopy of stained lesion samples for identification of Leishmania amastigotes.
The following definitions apply to the calculation of assay sensitivity and specificity: 1. True positive: Positive by both the CL Detect™ Rapid Test and the reference method.
2. False positive: Positive by the CL Detect™ Rapid Test but negative for the reference method.
3. True negative: Negative by both the CL Detect™ Rapid Test and the reference method.
4. False negative: Negative by the CL Detect™ Rapid Test but positive for the reference method.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the sensitivity and specificity of the FDA-cleared CL Detect™ Rapid Test when scraping is used to obtain tissue samples.
Time Frame: 1 day
|
Determine the sensitivity and specificity of the FDA-cleared CL Detect™ Rapid Test when scraping is used to obtain tissue samples.
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Max Grogl, Ph.D., Scientific Director
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LRDD-PERU-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leishmaniasis, Cutaneous
-
Medecins Sans Frontieres, NetherlandsUnknownOld World Cutaneous Leishmaniasis
-
Drugs for Neglected DiseasesWellcome Trust grant 212346/Z/18/Z - 21st Century Treatments for Sustainable...CompletedVisceral Leishmaniasis | Cutaneous LeishmaniasesUnited Kingdom
-
Hospital Universitário Professor Edgard SantosOswaldo Cruz Foundation; Conselho Nacional de Desenvolvimento Científico e...CompletedCutaneous Leishmaniasis, AmericanBrazil
-
Fundacion Nacional de DermatologiaHospital Dermatologico de Jorochito; Ministerio de Salud de Bolivia, Programa... and other collaboratorsCompletedCutaneous Leishmaniasis, AmericanBolivia
-
Centro Internacional de Entrenamiento e Investigaciones...University of TexasCompletedCutaneous Leishmaniasis (Diagnosis)Colombia
-
Knight Therapeutics (USA) IncCompletedCutaneous Leishmaniasis | Mucosal LeishmaniasisUnited States
-
Hospital Universitário Professor Edgard SantosInstituto Gonçalo Muniz FIOCRUZ BANot yet recruitingCutaneous Leishmaniasis, AmericanBrazil
-
Centro Internacional de Entrenamiento e Investigaciones...Universidad IcesiCompletedCutaneous Leishmaniasis, AmericanColombia
-
University of BrasiliaCompletedLocalized Cutaneous LeishmaniasisBrazil
-
U.S. Army Medical Research and Development CommandCompletedOld World Cutaneous LeishmaniasisTunisia
Clinical Trials on CL Detect™ Rapid Test
-
Foundation for Innovative New Diagnostics, SwitzerlandCompleted
-
Sky Medical Supplies & Equipments, LLCRecruitingCOVID-19 | Sars-CoV-2 InfectionUnited States
-
Lumos DiagnosticsRapid Pathogen ScreeningCompletedCovid19 | SARS-CoV-2United States
-
University of SouthamptonUniversity of Oxford; West Hertfordshire Hospitals NHS TrustCompleted
-
University of California, Los AngelesCompleted
-
Foundation for Innovative New Diagnostics, SwitzerlandBotswana Harvard AIDS Institute PartnershipCompletedCorona Virus InfectionBotswana
-
Abbott Rapid DxCompletedCOVID-19 | Influenza A | Influenza Type BUnited States
-
Corporacion Parc TauliCompleted
-
Centro Studi Internazionali, ItalyVivaChek Laboratories, Inc.UnknownCoronavirus InfectionsItaly